

Table e1. Reduction in OFF time and increases in good ON time (ON without troublesome dyskinesia) from the 4 randomized controlled studies (istradefylline versus placebo) that led to FDA approval.

Week	Placebo Good ON	Istradefylline 20 mg/day Good ON	Istradefylline 40 mg/day Good ON	Placebo OFF	Istradefylline 20 mg/day OFF	Istradefylline 40 mg/day OFF
Change from Baseline Study 1						
2	0.22 ± 2.81	-	1.57 ± 2.47	-0.37 ± 2.76	-	-1.92 ± 2.58
4	0.56 ± 2.28	-	1.4 ± 2.9	-0.91 ± 2.20	-	-1.63 ± 2.88
8	0.17 ± 2.54	-	1.49 ± 2.85	-0.52 ± 2.36	-	-1.58 ± 2.85
12	0.51 ± 2.68	-	1.58 ± 2.87	-0.69 ± 2.67	-	-1.86 ± 2.64
Change from Baseline Study 2*						
2	0.21	0.91	-	-0.47 ± 2.27	-1.46 ± 2.43	-
4	0.64	1.02	-	-0.65 ± 2.44	-1.49 ± 3.08	-
8	0.87	1.42	-	-1.25 ± 1.21	-1.65 ± 3.05	-
12	1.10	1.4	-	-1.05 ± 2.53	-1.57 ± 3.16	-
Change from Baseline Study 3						
2	0.45 ± 1.92	0.86 ± 2.04	0.83 ± 1.91	-0.47 ± 1.78	-0.99 ± 1.83	-1.06 ± 1.79
4	0.66 ± 2.10	1.11 ± 2.03	1.15 ± 2.40	-0.67 ± 1.79	-1.25 ± 1.76	-1.22 ± 2.09
8	0.53 ± 2.42	1.22 ± 2.31	1.19 ± 2.70	-0.46 ± 2.14	-1.25 ± 2.00	-1.35 ± 2.53
12	0.81 ± 2.48	1.4 ± 2.29	1.28 ± 2.80	-0.78 ± 2.08	-1.45 ± 2.03	-1.46 ± 2.69
Change from Baseline Study 4						
2	0.23 ± 1.55	0.86 ± 1.85	0.83 ± 2.15	-0.34 ± 1.59	-0.77 ± 1.67	-0.78 ± 1.87
4	0.36 ± 1.57	1.08 ± 2.30	1.05 ± 2.13	-0.41 ± 1.64	-0.89 ± 2.06	-1.03 ± 1.83
8	0.54 ± 2.07	1.00 ± 2.57	1.35 ± 2.20	-0.48 ± 2.28	-1.04 ± 2.21	-1.00 ± 2.12
12	0.25 ± 2.55	1.26 ± 2.37	1.05 ± 2.48	-0.3 ± 2.45	-1.20 ± 1.89	-0.95 ± 2.16

*Data are LS mean for good ON in Study 2